Japan Listing Unleashes Generic Sertraline Onslaught
This article was originally published in PharmAsia News
Executive Summary
Japan has listed a new batch of generic drugs in its reimbursement tariff that includes the first such competition to Pfizer’s antidepressant sertraline and Novartis's valsartan/amlodipine antihypertensive combo.